A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

被引:125
作者
Nasrallah, Henry A. [1 ]
Gopal, Srihari [2 ]
Gassmann-Mayer, Cristiana [2 ]
Quiroz, Jorge A. [2 ]
Lim, Pilar [2 ]
Eerdekens, Marielle [3 ]
Yuen, Eric [2 ]
Hough, David [2 ]
机构
[1] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA
[2] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Div Janssen Pharmaceut NV, Beerse, Belgium
关键词
paliperidone palmitate; schizophrenia; long acting; injectable; antipsychotic; efficacy; EXTENDED-RELEASE TABLETS; SOCIAL PERFORMANCE SCALE; DETECT CHANGE; DOUBLE-BLIND; SAFETY; RELIABILITY; RISPERIDONE; TOLERABILITY; ZIPRASIDONE; ADHERENCE;
D O I
10.1038/npp.2010.79
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Paliperidone palmitate is a long-acting injectable antipsychotic agent. This 13-week, multicenter, randomized (1 : 1 : 1 : 1), double-blind, parallel-group study evaluated the efficacy, safety, and tolerability of fixed 25, 50, and 100 milligram equivalent (mg equiv.) doses of paliperidone palmitate vs placebo administered as gluteal injections on days 1 and 8, then every 4 weeks (days 36 and 64) in 518 adult patients with schizophrenia. The intent-to-treat analysis set (N = 514) was 67% men and 67% White, with a mean age of 41 years. All paliperidone palmitate dose groups showed significant improvement vs placebo in the Positive and Negative Syndrome Scale (PANSS) total score (primary efficacy measure; 25 and 50 mg equiv., p = 0.02; 100 mg equiv., p < 0.001), as well as Clinical Global Impression Severity scores (p <= 0.006) and PANSS negative and positive symptom Marder factor scores (p <= 0.04). The Personal and Social Performance scale showed no significant difference between treatment groups. The overall incidence of treatment-emergent adverse events was similar between groups. Parkinsonism, the most frequently reported extrapyramidal symptom, was reported at similar rates for placebo (5%) and paliperidone palmitate (5-6% across doses). The mean body mass index and mean weight showed relatively small dose-related increases during paliperidone palmitate treatment. Investigator-evaluated injection-site pain, swelling, redness, and induration were similar across treatment groups; scores for patient-evaluated injection-site pain (visual analog scale) were similar across groups and diminished with time. All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia. Neuropsychopharmacology (2010) 35, 2072-2082; doi:10.1038/npp.2010.79; published online 16 June 2010
引用
收藏
页码:2072 / 2082
页数:11
相关论文
共 31 条
[1]   A RATING-SCALE FOR DRUG-INDUCED AKATHISIA [J].
BARNES, TRE .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :672-676
[2]   A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia [J].
Bhanji, NH ;
Chouinard, G ;
Margolese, HC .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (02) :87-92
[3]   Adherence to atypical antipsychotic treatment among newly treated patients:: A population-based study in schizophrenia [J].
Cooper, Dan ;
Moisan, Jocelyne ;
Gregoire, Jean-Pierre .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (06) :818-825
[4]   Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study [J].
Davidson, Michael ;
Emsley, Robin ;
Michelle, Kramer ;
Ford, Lisa ;
Pan, Guohua ;
Lim, Pilar ;
Eerdekens, Marile .
SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) :117-130
[5]  
*FRES KAB AB, 2007, INTR PRESCR INF
[6]  
[Gay W. Health P.R.B.N.I.o.M. Health P.R.B.N.I.o.M.], 1976, ECDEU Assessment Manual for Psychopharmacology, Revised, US Dept Health, Education, and Welfare publication (ADM), P534
[7]   Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics [J].
Gianfrancesco, Frank D. ;
Rajagopalan, Krithika ;
Sajatovic, Martha ;
Wang, Ruey-hua .
PSYCHIATRY RESEARCH, 2006, 144 (2-3) :177-189
[8]  
GOPAL S, 2010, INT CLIN PSYCHOPHARM
[9]  
Hough D., 2008, BIOL PSYCHOL, p285S
[10]   Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia [J].
Hough, David ;
Lindenmayer, Jean-Pierre ;
Gopal, Srihari ;
Melkote, Rama ;
Lim, Pilar ;
Herben, Virginie ;
Yuen, Eric ;
Eerdekens, Marielle .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (06) :1022-1031